0117 Phase 3 study of tenofovir alafenamide vs placebo in HIV-1 adults

• Research type

  Research Study

• Full title

  A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

• IRAS ID

  138247

• Contact name

  Margaret Johnson

• Contact email

  margaret.johnson1@nhs.net

• Sponsor organisation

  Gilead Sciences. Inc.

• Eudract number

  2013-002830-19

• ISRCTN Number

  not provided

• REC name

  London - Central Research Ethics Committee

• REC reference

  13/LO/1524

• Date of REC Opinion

  21 Nov 2013

• REC opinion

  Further Information Favourable Opinion